Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma

Brief summary (registry, in English)

Objective: To investigate the failure patterns, efficacy and safety of thoracic radiotherapy combined with EGFR-TKI in stage III unresectable non-small cell lung cancer harboring EGFR-sensitive mutations. Methods: This is a multicenter retrospective cohort study. Patients diagnosed with stage III unresectable EGFR-mutant non-small cell lung cancer who received thoracic radiotherapy plus EGFR-TKI between January 1, 2020 and December 31, 2024 were enrolled from five hospitals in Guangxi, including Laibin People's Hospital, The People's Hospital of Chongzuo, Liuzhou Traditional Chinese Medical Hospital, The First People's Hospital of Yulin, and The First Affiliated Hospital of Guilin Medical University. We will analyze progression patterns, progression-free survival, overall survival and treatment-related adverse events.

What you commit to

• Study type: Observational
• Participants enrolled: 202
• From 1 Jan 2020 to the primary completion date, 31 Dec 2024
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.